

CURRICULUM VITAE

NAME: HAKIM, Antoine M.

DATE OF BIRTH: April 30, 1942

OFFICE ADDRESS: University of Ottawa
Ottawa Health Research Institute
Neuroscience Research Program
The University of Ottawa
2413 - 451 Smyth Road
Ottawa, Ontario, K1H 8M5

TELEPHONE: (613) 562-5462

FAX: (613) 562-5403

E-MAIL: ahakim@ohri.ca

LANGUAGES: Fluently bilingual in French and English

EDUCATION:

1975 **M.D.**
Albany Medical College, Albany, New York, USA.

1971 **PhD Biomedical Engineering**
Rensselaer Polytechnic Institute, Troy, New York, USA
Supervisor: Dr. Gerald Moss, Professor of Biomedical Engineering
Thesis: "Quantitation of the contribution of the pentose phosphate pathway to brain glucose metabolism"

1967 **MSc Chemical Engineering**
University of Alberta, Edmonton, Alberta.

1964 **BSc Chemical Engineering**
Washington State University, Pullman, WA, USA

POSTGRADUATE AND OTHER EXPERIENCE

1979-1980 Postdoctoral Fellowship, Cerebral Metabolism
Montreal Neurological Institute and Hospital
Montreal, Quebec
Supervisor: Dr. H. Pappius

1976-1979 Resident in Neurology
Montreal Neurological Institute and Hospital
Montreal, Quebec.

1975-1976 Categorical Intern in Internal Medicine
Albany Medical Center Hospital, Albany, New York.

1967-1968 Instructor of Physics, grades XI and XII, Commission des Écoles
Catholiques de Montréal.

1965-1967 Research Engineer, Syncrude Canada Ltd., Edmonton.

CERTIFICATION

1984	Fellow of the American Board of Psychiatry and Neurology
1980	Fellow of the Royal College of Physicians & Surgeons of Canada Neurology
1979	Specialist Certificate, Neurology, Corporation Professionnelle des Médecins du Québec

APPOINTMENTS

University and Institute

2001-present	Site-Director Heart & Stroke Foundation Centre for Stroke Recovery
2005-2008	Scientific Director Heart & Stroke foundation Centre for Stroke Recovery
2001-present	Director, Neuroscience Research Program, Ottawa Health Research Institute University of Ottawa
2000-present	CEO and Scientific Director, Canadian Stroke Network
1992-present	Cross appointment - Cellular and Molecular Medicine, University of Ottawa
1992-present	Cross appointment to Graduate & Post Doctoral Studies,
1992-present	Professor and Chair, Neurology, University of Ottawa
1992-2001	Director, Neuroscience Research Institute, University of Ottawa
1991-1992	Professor, Department of Neurology and Neurosurgery, McGill University
1984-1991	Associate Professor, Department of Neurology and Neurosurgery McGill University
1982-1983	Assistant Professor, Department of Neurology and Neurosurgery McGill University
1979-1982	Lecturer, Department of Neurology and Neurosurgery, McGill University
1975-1976	Adjunct Assistant Professor, Department of Biomedical Engineering Rensselaer Polytechnic Institute, Troy, New York

Hospital

2001-present	Senior Neurologist, The Ottawa Hospital
1992-2001	Division Head, Division of Neurology, The Ottawa Hospital
1987-1992	Consulting Neurologist, Jewish General Hospital, Montreal
1986-1992	Coordinator, Cerebrovascular Disease Research, Montreal Neurological Institute
1986-1991	Coordinator, McConnell Brain Imaging Centre, Montreal Neurological Institute
1985-1986	Associate Coordinator, McConnell Brain Imaging Centre Montreal Neurological Institute
1984-1992	Associate Neurologist, Royal Victoria Hospital, Montreal
1984-1992	Associate Neurologist, Montreal Neurological Hospital
1979-1992	Consulting Neurologist, Montreal Chest Hospital, Montreal
1979-1983	Assistant Neurologist, Royal Victoria Hospital, Montreal
1979-1983	Assistant Neurologist, Montreal Neurological Hospital

RESEARCH

1. Research Activities

A. Laboratory Studies

My laboratory-based research activities were frequently guided by my clinical exposure to patients with neurological problems. During my neurology residency I was intrigued with Wernicke-Korsakoff patients who exhibit severe memory deficits in association with alcoholism and thiamine deficiency but show only very limited brain lesions. I began to study how systemic conditions result in focal brain damage. This led to an interest in stroke because of the selective nature of the damage caused by ischemic deprivation. Specifically, my fundamental research activities have included:

Investigation of the biochemical, ionic, molecular and receptor events that determine cerebral vulnerability in metabolic deficiencies and in stroke:

My laboratory described the focal cerebral events that precede the appearance of pathological damage during prolonged deficiency of thiamine and B12. In these settings, and subsequently in focal ischemia, we correlated in time and space the glucose utilization and acidosis that precede the focal appearance of histologically evident damage, and showed how reversing the metabolic or vascular deficiency resulted in a specific sequence of reversal of these metabolic abnormalities, e.g. the appearance of alkalosis. The simultaneous measurement of pH and glucose utilization or blood flow was made possible by an innovation to autoradiography we developed involving sublimation of the pH marker after we had measured its radioactivity in brain.

Subsequently, I focused on cerebral ischemia and correlated hyperglycemia with the severity of focal acidosis in that setting. The association of hyperglycemia with worsened outcome in stroke was subsequently shown in stroke patients. Concepts derived from our animal studies guided studies we performed in stroke patients in the acute phase, using Positron Emission Tomography (PET). We correlated in these patients the anatomic-metabolic-functional parameters with focal cerebral blood flow changes and radiological/clinical outcomes. These studies allowed us to describe the ischemic penumbra in patients and show its progression in time and space. We went back to the animals and showed that cells in the penumbra region die by apoptosis while those in the ischemic core die by necrosis, and verified that as the ischemia becomes more prolonged necrosis sweeps over regions of apoptosis. This led us to investigate the molecular determinants of apoptotic cell death, and we showed that cyclin-dependent kinases trigger apoptosis and that inhibiting them leads to neuroprotection. We also reported that activating neuronal-apoptosis-inhibitory-protein (NAIP) provides neuroprotection in the setting of apoptotic cell death.

My laboratory also reported the dependence of calcium channel activity on focal blood flow changes, and in an ischemia-reperfusion model, showed the reversibility of calcium channel activation with associated tissue survival. In the stroke patients, we used PET to study the effect of administering nimodipine on metabolic function. Because clinical trials were contemplated with nimodipine, we studied and reported the kinetics of binding of nimodipine *in vivo*, which allowed us to suggest in various forums the enormous challenge this agent would face as a therapeutic modality.

Determination of conditions for neuroprotection against ischemic damage:

We first studied the relevance of interstitial glutamate levels on selective vulnerability in ischemia by correlating glutamate levels with activity of the calcium channels and histological outcome. This led us to investigate the concept of preconditioning, whereby short-duration ischemia, cortical depolarization, exposure to excitatory amino-acids or activation of calcium channels can improve the brain's resistance to subsequent ischemic damage. First, we described how short term global ischemia protects against subsequent focal ischemic

damage, and then more thoroughly studied cortical spreading depression (CSD) as a laboratory tool to explain the preconditioning phenomenon and potentially use it therapeutically. We showed that CSD activated neurotrophic factors, decreased intra-ischemic glutamate levels, and down-regulated the transporters of the excitatory amino acids. More recently, we showed a number of molecular correlates of CSD, including a recent submission describing the changes in inflammatory cytokine protein levels in brain and plasma following CSD. My research colleagues and I are currently directing our attention to the modulation of a limited number of factors thought to play a role in the neuroprotective cascade.

Investigation of post-stroke plasticity and means of enhancing it:

My laboratory showed the regulation of nestin expression in focal brain injury. This is one of several developmental proteins activated in focal ischemia. Our special attention to this protein arose from our correlation of its activation with the mobilization of stem cells following focal ischemia, confirming that nestin is an essential protein in stem cell guidance. We have also published on the effect of low-dose amphetamine in patients recovering from stroke. This work has implications for our understanding of recovery and therapy after stroke.

B. Clinical Research Activity

My clinical studies focused on understanding the cerebral vulnerability to ischemia. I used PET in stroke patients to distinguish brain regions where cells are committed to die from those where they are still alive but not functioning, and tested the effect of various therapies administered in the acute phase on brain metabolic and perfusion parameters and correlated these with clinical and radiologic outcomes. I also contributed to studies which confirmed that, in stroke associated with atrial fibrillation, Coumadin was the appropriate therapy to prevent stroke recurrence. More recently we reviewed the lessons learned from negative stroke trials in an article titled: "Toward Wisdom from Failure: Lessons Learned from Negative Stroke Treatment Trials and New Therapeutic Frontiers". In this article, we outlined the shortcomings shared by previous stroke trials and described the experiments needed to increase the likelihood of success in translational stroke studies, a theme subsequently confirmed by the STAIR group. More recently, using data from the Registry of the Canadian Stroke Network, we reported the effect of calcium channel blockers on the outcome from stroke and showed that they could be beneficial. We are currently studying, using the data set in the Registry, the influence of statins on vulnerability to bleeding in response to t-PA in stroke patients. Earlier this year, we submitted a proposal to our Institutional Review Board to evaluate the response of stroke patients to Granulocyte Colony Stimulating Factor, an agent which releases bone marrow stem cells into the circulation and which may accelerate recovery from stroke.

2. Changing the Approach to Stroke Research and Care in Canada and Beyond

In 1999 a number of my colleagues, both scientists and clinicians, asked me to lead an application to establish the Canadian Stroke Network (CSN). Although this was a very competitive process, we were successful and were awarded a term of seven years, at \$4.5M per year. I am the CEO and Scientific Director of the CSN. This organization brought together more than 100 scientists and clinicians to work collaboratively within a broad partnership that includes the academic research centres, the Heart and Stroke Foundation, industry and government. CSN's research falls within four themes: "Better Stroke Prevention", "Optimizing Acute Stroke Care", "Reducing Cell Death and Minimizing Stroke Damage", and "Enhancing Brain Repair and Functional Recovery Post-Stroke". In addition to research and partnership development around stroke, the CSN accepted the mandate of preparing the future generation of stroke researchers and care givers. The CSN's ultimate goal is the alleviation of the burden of stroke to the individual, their family, and to the nation.

In its first term the CSN has established a new approach to stroke research. Multi-disciplinary, inter-institutional collaborations were formed to address major research challenges in the field of stroke and to ensure that the results of this research are translated into health and economic

benefits. This approach produced a number of important research contributions. CSN scientists evaluated a potential role for stem cells in stroke, described the role of TRPM7 channels in imparting ischemic vulnerability and developed a blocker for them which are now being tested in phase I-II trials. CSN scientists also showed calcium movement in previously-unknown hemichannels which may activate inflammatory pathways. Based on a thorough review of the world literature, experts within CSN have also determined the best practices in stroke rehabilitation, and these are currently being tested in trial settings. The Registry of stroke patients has allowed a number of correlations between premorbid physiological and social characteristics of patients and stroke outcomes. Finally, in its first term the CSN put together a broad financial partnership which contributed to training 45 stroke scientists and clinicians.

The CSN has just been awarded a second seven year term, with an unprecedented 35% budget increase, to continue its research and to establish and promote a Canadian Stroke Strategy (CSS). The Strategy, devised by the CSN in partnership with the Heart and Stroke Foundation of Canada, is a plan that starts with the premise that the best stroke research must be moved into practice. This strategy builds on the interactions developed by the CSN between basic researchers, clinicians and partner organizations and has been gaining momentum over the last four years. Working with health-care providers, patients, stroke champions, local partners and dedicated politicians, the CSN is committed to change the delivery of stroke care by ensuring the most recent stroke knowledge is transferred to health-care providers and implemented with patients. In prevention, the CSS proposed a broad coalition aimed at setting up stroke prevention clinics across the country. In acute therapy, the CSS instituted a program of national education not only of the public, but also of health care providers, thus bringing about a change in the delivery of acute stroke care through coordination of services and implementation of best practice.

This has resulted in very substantial improvement (sometimes ten-fold increases) in the rate of t-PA administration in several Canadian sites. This is the only known treatment for stroke, but it is time sensitive requiring coordination of responses at various points in the care continuum. In rehabilitation, the CSS has identified what works, sponsored a double-blind trial to test it further, and proposes a substantial increase in the services available to improve functional recovery after stroke. Most recently, an economic analysis of the Canadian Stroke Strategy showed that applying these principles would not only result in fewer strokes and better outcomes, but also result in substantial savings to the treasury after all costs are covered. Across Canada eight provinces are in various stages of implementing stroke strategies using the models we have developed. As the Strategy becomes established the CSN looks forward to increasing further the coordination between stroke research and stroke prevention and care. This will accelerate the translation of stroke knowledge and facilitate the closing of care "gaps" identified by the Strategy.

Despite my growing commitment to improving stroke care in Canada and beyond, I have also been concerned that we need to recognize the changing realities of the stroke process itself. The literature suggests that there is a significant increase in the prevalence of covert strokes, small infarcts located in the white matter, which do not result in sudden major neurological deficits but cumulatively can cause dementia. It is estimated that these occur at 8-10 times the frequency of major catastrophic strokes and may be a consequence of the increase in life-expectancy, obesity and diabetes in western society. I have described a hypothesis regarding covert strokes titled "Living Beyond Our Physiological Means: Small Vessel Disease Of The Brain Is An Expression Of A Systemic Failure In Arteriolar Function. A Unifying Hypothesis" which impressed the editorial board of the Journal STROKE sufficiently to bestow on it an "Innovation Award". The hypothesis suggests that small vessel disease is due to occlusion of arterioles, results from an inflammatory process, and in the same individuals will not only affect their brain with covert strokes leading to dementia, but also their retina leading to macular degeneration and their kidneys leading to renal failure. The article, which was published in May 2009, recommended various health care approaches to improve prevention and management of this systemic illness. I will follow it with an article on innovative approaches to managing hypertension world-wide, the major risk factor for small and large strokes.

It has also been a particular source of pride to the CSN to be advised that a coalition of European countries has proposed the establishment of a European Stroke Network patterned on the CSN, and asked me to chair its Scientific Advisory Board. In addition, I was honoured to be invited by Dr. Joel Ménard in France, who was assigned by President Sarkozy the responsibility of establishing a national strategy against Alzheimer's disease, to spend a few days advising him and his colleagues on the most effective methods to alleviate the burden of vascular disease in France. This visit, which occurred in April/May 2009, was supported by the French Government and was very successful in its mission, and identified a number of areas where international collaborations may be possible. I have also been advised by the Spanish Society of Neurology that they are inviting me to their 2009 meeting to address them on the organization of stroke care, as the Spanish Ministry of Health had approved the establishment of a National Stroke Strategy for Spain. I am honoured that they will award me their Thomas Willis Prize at the meeting. Closer to home, NINDS and CSN are exploring a partnership in translational stroke research.

3. Other Responsibilities for Research Administration

In 2005, I accepted the Directorship of the Centre for Stroke Recovery, formed in 2002 as a partnership between the Heart and Stroke Foundation of Ontario, the Ottawa Health Research Institute, Baycrest Centre for Geriatric Care, and Sunnybrook Health Sciences Centre. The Centre for Stroke Recovery, with an annual budget of \$1.2M supports an integrated approach to identifying, through multi-disciplinary research, the most effective means of promoting and sustaining stroke recovery. It links knowledge, skills, expertise and advanced technologies from the prominent research groups in the areas of brain recovery and stroke rehabilitation located at the three sites. The Heart and Stroke Foundation of Ontario has been so thrilled with the output from this Centre that it made a commitment to raise \$25M for the Centre. The figure announced for the fund to date has already reached almost \$30M !!

In addition to the national leadership responsibility implied by the Canadian Stroke Network, Canadian Stroke Strategy and the Heart and Stroke Foundation Centre for Stroke Recovery, I have been the Chair of Neurology and the Director of Neuroscience Research at the University of Ottawa since 1992, and the Director of the Neuroscience Research Program of the Ottawa Health Research Institute since 2001. A 2005 Survey by "Science Watch", an organization that evaluates research effectiveness, identified the Neuroscience Research Program at the University of Ottawa as the group publishing neuroscience manuscripts with the highest per capita impact in Canada. This level of excellence was achieved through a three-fold approach: 1) a demanding selection and evaluation process that precedes recruitment; 2) the ability to put together recruitment packages that are competitive with other institutions; and 3) selection of excellent individuals who value collaboration as well as personal success. This was made possible by nurturing a strong relationship with private donors and foundations, and developing well-conceived partnerships that lead to synergies with the private sector

HONOURS RECEIVED

1. Hans-Chiari Award – Present the "Hans-Chiari Lecture at the Joint Meeting of the Austrian and the Hungarian Stroke Societies, Friday, January 21, 2011, Vienna, Austria.
2. PIR Biomedical Science Ambassador Award (Scientific Category) at The Partnership In Research, The Ottawa Evening 2010" Gala in celebration of Canada's World-Class Achievements – May 12, 2010.
3. Heart & Stroke Foundation of Canada – Merit Award – February 6, 2010
4. Awarded the 2009 Thomas Willis Prize by the Spanish Society of Neurology November 2009.
5. September 2009, the Heart and Stroke Foundation of Ontario announced an annual research grant of \$100,000 to be named the "Dr Tony Hakim Innovative Stroke Research Award" for an "out of the box" project proposal in the field of stroke recovery.
6. Invited, supported by the French Government, to advise them on their national strategy against Alzheimer's disease – April-May 2009.

7. 2nd Prize Winner of the Journal STROKE's Innovation Award for article submitted entitled: "Living Beyond Our Physiological Means: Small Vessel Disease Of The Brain Is An Expression Of A Systemic Failure In Arteriolar Function. A Unifying Hypothesis." Stroke. Accepted Dec 2008 and published May 2009.
8. Dr. J. David Grimes Research Career Achievement Award, The Ottawa Health Research Institute, November 2008.
9. Consultant to select Director of the Florey Neuroscience Institute, Australia. Florey is an amalgamation of three existing institutes (National Stroke Research Institute, Brain Research Institute, Howard Florey Institute) - January 2008.
10. Personality of the Year - presented by LeDroit and CBC Radio -2008
11. Participated (by invitation only) in the Princeton Stroke Conference, Houston, Texas – March 28, 2008
12. Chair, Scientific Advisory Committee, the European Stroke Network, 2007 - present.
13. Advisor to the French Strategy against Alzheimer Disease. 2007-2009.
14. Member of the Board of Directors, Fonds de la Recherche en Santé du Quebec, 2007 - present.
15. Received the MEDEC Award for Medical Achievement from Canada's Medical Device Technology Companies, 2007.
16. Received the Thomas Willis Award, a Lifetime Achievement Award from the American Stroke Association and delivered the Thomas Willis Lecture at the International Stroke Conference in San Francisco on February 7, 2007.
17. Appointed Officer of Order of Canada, announced in February 2007.
18. Admitted as a Fellow to the Canadian Academy of Health Sciences, September, 2005
19. Ottawa Life Sciences Council Career Achievement Award for raising the profile of stroke in Canada and putting it on the national agenda. November, 2004.
20. Canadian Stroke Consortium Award of Excellence, 2000
21. Selected CEO and Scientific Director - Canadian Stroke Network, a Network of Centres of Excellence, 1999 - 2006. Network renewed for another 7-year term in 2005.
22. Selected Scientific Director, the Heart and Stroke Foundation Centre for Stroke Recovery, 2005.
23. Selected Program Leader - Ottawa Stroke Consortium for Applied Research - a Program Grant funded by the Heart and Stroke Foundation of Ontario, 1995 - 2000
24. Member, Advisory Board - Institute for Biological Sciences, NRC, 1995 - 2000
25. Member, Scientific Advisory Board - Allelix Biopharmaceuticals, 1994 - 1997
26. Member, Registry of world thought leaders in stroke, Health Science Communications.1997
27. Elected member of the International Committee - International Stroke Society, 1996.
28. Invited to join Research Policy Committee, Heart & Stroke Foundation of Ontario, 1996.
29. Recipient, Heart and Stroke Foundation of Ontario's "Stroke Award", 1995.
30. Named "Researcher of the Year", Ottawa General Hospital, 1995.
31. Chair -Neuroscience Council, University of Ottawa, 1994-present.
32. Elected member of Board, Heart and Stroke Foundation of Ontario, 1994.
33. Elected to Health Science Policy Council of the Heart & Stroke Foundation of Canada, 1994.
34. Elected Councillor - Canadian Neurological Society, 1991.
35. Elected member of the Board of Governors of the Low-Beer Family Foundation, 1988-1990.
36. Elected to the Advisory Board of the Montreal Neurological Institute as a Staff Representative, 1988-1991
37. Selected as the Aitken Lecturer, Univ. of Western Ontario, London, ON, 1988.
38. Chairman of Scientific Committee - XIII International Symposium on Cerebral Blood Flow and Metabolism, Montreal, Quebec, June 1987.
39. Elected to the American Neurological Association, 1984.
40. Recipient of the "Jonathan Ballon Award" - The Quebec Heart Foundation's award for the most promising applicant for grant-in-aid in 1984. Title of Application: Investigation of Cerebral Acidosis in Ischemia.

GRANT REVIEWS AND SITE VISITS

1. Invited reviewer and Chair – The Scientific Advisory Board for the European Stroke Network. Participated in 2nd review panel - Heidelberg, Germany, September 8, 2010.
2. Invited reviewer and Chair – The Scientific Advisory Board for the European Stroke Network. Participated in first review panel - Stockholm, Sweden-May 26, 2009.
3. Invited reviewer, the UK Stroke Research Network – January 21, 2009.
4. Invited and participated in the second round of the German Excellence Initiative -review panel of "Neuroscience" - Bonn Germany - July 2007
5. Invited and participated in the Michael Smith Foundation for Health Research review panel for Technology/Methodology Platform. February 5, 6, 2007 in Vancouver.
6. Invited and participated in the review of Centres of Excellence set-up by Fonds de la Recherche en Santé du Quebec (FRSQ), Réseau Sante Cardiovasculaire sante respiratoire (January 24, 2007)
7. Invited and participated in the review of Centres of Excellence set-up by Fonds de la Recherche en Santé du Quebec (FRSQ), Réseau Sante Cardiovasculaire sante respiratoire (February 2006)
8. Member, Scientific Review Committee for Chercheurs Nationaux, FRSQ, 1999-2000
9. Member, Scientific Review Committee for Chercheurs Boursiers, FRSQ, 1985-1988
10. Participation in NIH-conducted site visit to the imaging program proposed by the Massachusetts General Hospital, Harvard University, 1987.
11. Chairman, Scientific Review Committee and Member of Executive of the Heart and Stroke Foundation of Canada, Committee III: Stroke, neurophysiology and neuroregulation 1989-1992.
12. Member, MNI Collaborative Industry Academic Research Committee, 1990.
13. Member, Medical Research Council, Neurosciences "B" Panel, 1993-1996.
14. Reviewer for International Human Frontier Science Organization.

RESEARCH TRAINEES SUPERVISED

Currently in Laboratory of Cerebral Ischemia (*Country identified if student/fellow not from Canada*)

• Wafa Juma	2006-Present	masters student
• Rema Kamal	2005-Present	honour student
• Nzau Munyao	2005-Present	MD, collaborator

Previously in Laboratory of Cerebral Ischemia

• Sarah Schock	2002-2008	PhD. Student
• Hale Sayan - <i>Turkey</i>	2004	Post Doctoral Fellow
• David Banner	2000	M.Sc. Student
• Isabella Moroz	2002	Post Doctoral Fellow
• Ava Chow	2000-2002	PhD. Student
• Nobuaki Shinohara, M.D. - <i>Japan</i>	1999-2001	Research Fellow
• Andre G. Douen, M.D., Ph.D., FRCPC	1997-1999	Fellowship
• Yutaka Kametsu, M.D. - <i>Japan</i>	1997-1999	Fellowship
• Joseph P. Tauskela, Ph.D.	1997-1999	Fellowship
• Sachiko Osuga, M.D. - <i>Japan</i>	1997-1998	Fellowship
• Vladimir Skljarevski, M.D.	1996-1997	Fellowship
• Katsunori Akiyama, M.D. - <i>Japan</i>	1995-1997	Fellowship
• Lynda McGahan, M.Sc.	1994-1996	M.Sc. Student
• Kazushi Matsushima, M.D - <i>Japan</i> .	1993-1996	Fellowship
• Hitoshi Osuga, M.D., Ph.D - <i>Japan</i> .	1992-1993	Fellowship
• Ben Guiot, M.D.	1992-1993	Fellowship
• Mukul Sharma, M.D.	1991-1992	Fellowship
• Dale Corbett, Ph.D.	1991-1992	Visiting Scientist
• Alan Hazell, Ph.D.	1990-1994	Ph.D. Student

• Shunya Takizawa, M.D., Ph.D. - <i>Japan</i>	1989-1991	Fellowship
• Matthew Hogan, M.D., Ph.D., FRCP	1988-1991	Fellowship
• Steven Vogel, M.Sc.	1986-1989	M.Sc. Student
• Leo Berger, M.D., FRCP	1986-1988	Fellowship
• Marie Arrieta	1985-1986	Special Project

Previously in McConnell Brain Imaging Unit, with Direct Supervision by Dr. Hakim

• Curt Beil, M.D. - <i>Germany</i>	1986-1987	Fellowship
• Suzanne Dyve, M.D. - <i>Denmark</i>	1986-1987	Fellowship
• Gilles Marchal, M.D. - <i>France</i>	1986-1988	Fellowship
• Jose Villanueva, M.D. - <i>Spain</i>	1985-1986	Fellowship
• Ronald Pokrupa, MD, FRCSC	1983-1984	Fellowship

ORGANIZATION OF STROKE EVENTS, INVITATIONS TO SPEAK AND PARTICIPATION IN CONFERENCES, SYMPOSIA AND WORKSHOPS

1. Hans-Chiari Award – Present the “Hans-Chiari Lecture at the Joint Meeting of the Austrian and the Hungarian Stroke Societies, Vienna, Austria - January 21, 2011. Title: The Canadian Stroke Initiative: Solutions for Stroke Networks.
2. Invited to speak – Resident Research Day, The Ottawa Hospital, Ottawa, Ontario, October 12, 2010
3. Key note speaker – Canada-China Joint Workshop on “Frontiers in Biomedical Research”, Ottawa, Ontario – October 1, 2010. Title: Stroke is very scary.... But preventable.
4. Invited to speak – HSFOCSR fundraising event, Richmond Hill, Ontario, September 21, 2010. Title: Stroke: Prevention, Diagnosis, Treatment.
5. Invited to speak at RGP Regional Geriatric Rounds, Ottawa, Ontario, June 25, 2010. Title: Stroke and Seniors.
6. Canadian Stroke Network 1st International Stroke Congress – Quebec City, Quebec, June 6-8, 2010 – over 1,000 participants.
7. Invited to speak at the International Brain Research Organization, Ottawa, Ontario, May 20, 2010. Title: Healthy Brains in Healthy Bodies.
8. Invited to speak at the Canadian Association of Neuroscience Annual Meeting, Ottawa, Ontario, May 15, 2010. Title: Stroke Scarier than you thought...but still preventable.
9. Invited to speak at Heart and Stroke Foundation of Ontario, Toronto, Ontario, Donors Event, May 5, 2010. 40 Years of Cerebrovascular Care: What’s Next – shorter version.
10. Invited to speak to University of Lille, France, April 1, 2010. Title: STROKEAVENIR.
11. Invited to speak to University of Ottawa Medical Students, February 3, 2010. Title: Stroke and Its Impact.
12. Invited to speak at Rounds at the Montreal Neurological Institute, Montreal, Quebec, January 8, 2010. Title: Progress and Challenges in Stroke Prevention and Treatment.
13. Invited to speak at the Heart & Stroke Foundation of Ontario, Toronto, Ontario, Clinical Impact Workshop, December 11, 2009. Title: 40 Years of Cerebrovascular Care: What’s Next.
14. Invited to speak at the HJM Barnett Lecture Thunder Bay, Ontario December 2, 2009. Lecture Title: Achievements & Challenges in Vascular Care: A Canadian Perspective; and on December 3, 2009. Lecture Title: Future Horizons in Stroke.
15. Invited to speak at the Thomas Willis Conference (awarded the Thomas Willis Award) during the Annual Meeting of the Spanish Neurological Society in Barcelona, Spain, November 18, 2009. Lecture Title: The Experience of the Canadian Stroke Network: Bringing Knowledge to Practice.
16. Invited to speak at the Gerontological Nursing Association Annual General Meeting & Conference, Ottawa, Ontario, November 6, 2009. Lecture Title: Stroke and Seniors.
17. Invited to speak – Rounds, The Ottawa Hospital, October 23, 2009. Lecture Title: STROKE More Scary than You Thought.....but preventable.
18. Invited to speak at the AIM 2009, Toronto, ON October 17, 2009. Lecture Title: Canadian Stroke Strategy: Cross-country Progress and Impact.

19. Invited to speak at the Autorité sanitaire régionale Séance d'éducation médicale Bathurst, New Brunswick, October 8, 2009. Lecture Title: La nécessité de s'organiser contre les AVC
20. Invited to speak at the Boehringer Ingelheim GmbH, Advisory Board Meeting, September 12, 2009, Florence, Italy. Lecture Title: Why do only less than 5% of eligible patients get stroke lysis?
21. Invited to speak at the Canadian Stroke Strategy Steering Committee, September 29, 2009, Newfoundland. Lecture Title: Organized Stroke Care.
22. Invited Speaker – OHRI Scientist Retreat, Merrickville, Ontario, May 14, 2009. Lecture Title: Big troubles from small strokes – and what you can do about them.
23. Invited Speaker - as a Visiting Lecturer in Paris, Lille and Dijon, France: April 24, 2009 - Hôpital Lariboisière, Lecture title: "Brain small vessel disease is a systemic condition". April 28, 2009 – CHU-Lille, Lecture title: "The Canadian Stroke Network: Accomplishments and Challenges". May 5, 2009 – Dijon, Lecture title: "Lessons from the Registry of the Canadian Stroke Network".
24. Invited Speaker – Board of Directors, Heart and Stroke Foundation of Canada. Ottawa, ON, April 18, 2009. Ottawa
25. Invited Speaker – Title: Stroke and Its Impact – Medical Student Interest Group in Neurology (SIGN) at the University of Ottawa, November 5, 2008.
26. Invited Keynote Speaker – Title: The Hidden Dimensions of Stroke – Alberta Stroke Conference, Canmore Alberta, November 1, 2008.
27. Invited Speaker – Title: La Stratégie canadienne de l'AVC appuie la mise en œuvre de stratégies par les provinces, Quebec Stroke Summit, Montreal, Quebec, October 7, 2008.
28. Invited Speaker – Title: Vascular Cognitive Impairment is a Systemic Disease - Genesis Lecture club on dementia, Ottawa, ON, October 6, 2008
29. Invited Speaker – Title: The Experience of the Canadian Stroke Network – Bringing Knowledge to Practice – 6th World Stroke Congress, Vienna, Austria – September 27, 2008
30. Invited Speaker – Stroke Care in Canada - 2nd National Stroke Rehabilitation Conference, Winnipeg, Manitoba – September 18, 2008
31. Invited Speaker as the Richardson Lecturer – Title: Neurovascular Disease: Impact in the 21st Century, Canadian Neurological Sciences Federation Conference, Victoria, BC – June 18, 2008.
32. Keynote Speaker - Title: The Canadian Stroke Network - Eurostroke Kick-off Meeting - Berlin, Germany - March 9, 2008.
33. Keynote Speaker - Title: Expanding the Universe of stroke, Kiwanis Medical Foundation Luncheon Meeting - Ottawa, Ontario - February 22, 2008.
34. Invited Speaker - Title: Changing Stroke Care Systems: The Canadian Experience, 2nd Russian International Congress Cerebrovascular Pathology and Stroke, St. Petersburg, Russia - September 19, 2007.
35. Chair Symposium - Interventional technologies of stroke treatment, 2nd Russian International Congress Cerebrovascular Pathology and Stroke, St. Petersburg, Russia - September 19, 2007.
36. Delivered the Thomas Willis Lecture at the American Stroke Association, 2007 International Stroke Conference in San Francisco, US on February 7, 2007.
37. Participated in a Platform Award Program Full Application Review Panel for the Michael Smith Foundation for Health Research in Vancouver on February 4th, 5th & 6th, 2007.
38. Chair, of the Assessment Committee 2007 Thematic Networks Centre of Research of the FRSQ January 24th & 25th, 2007.
39. Invited to give a Workshop entitled Cerebrovascular Risk Management at the Heart and Stroke Foundation Clinical Update 2006 at the Toronto Convention Centre December 9, 2006.
40. Participated in the fourth meeting of the Project of Development of a continuum of services for the people Victims of a Cerebral Vascular Accident or at Risk to become to the Ministry of Health and Welfare departments of Quebec, November 1, 2006.
41. Developed and participated at an AllerGen and Canadian Stroke Network Workshop to Discuss Research Opportunities in Inflammation and Stroke - Delivered a Presentation regarding Vascular Risk Factors, Montreal - October 24, 2006.
42. Invited Speaker - Rounds - Title of Talk: Clinical Challenges of Stroke, Winnipeg, Manitoba - September 29, 2006.

43. Participated in the 2nd Foundation Roundtable on Healing and the Arts - Mental Health and the Arts in Ottawa – National Arts Centre, September 27, 2006
44. Participated and developed in NINDS Stroke PRG Meeting/Workshop in Washington, US - September 19, 2006.
45. Participated in 2nd National Stroke Conference in Ottawa - September 16th and 17th, 2006.
46. Met with Saskatchewan Health Authorities to engage in Stroke policy planning for the Province of Saskatchewan - September 6th and 7th, 2006.
47. University of Ottawa Eye Institute, Scientific Advisory Committee, Potential Chair in Clinical/Translational Research in the Prevention of Blindness from Age Related Macular Degeneration. Delivered a presentation entitled Vascular Disease Research in Ottawa - August 29, 2006.
48. Participated in a nationally televised media conference at the National Press Theatre in Ottawa to announce the results of an economic analysis on the cost of stroke disease in Canada and the need for a Canadian Stroke Strategy. Conducted extensive media interviews and the event received coverage in more than 140 media outlets in June 2006.
49. Met with Ministries of Health to engage in stroke policy planning: Quebec February 2006, Newfoundland May 2006, Manitoba April 2006. The visit in Manitoba included meeting the Minister of Health who was convinced of the need to establish an integrated stroke strategy in his province.
50. Organized the Annual General Meeting of the Canadian Stroke Network. This has become the largest annual forum for stroke research and care in Canada 2000-2006.
51. Invited participant. 25th Princeton Conference. Portland, Oregon, May 2006
52. Invited Speaker - Society of Rural Physicians of Canada - "The Challenges of Modern Stroke Care in the Rural Setting", Winnipeg, Manitoba, April 21, 2006.
53. Invited Speaker – Heart & Stroke Clinical Update – “Cerebrovascular Disease: Hypertension As a Risk Factor”, Toronto, Ontario, December 10, 2005
54. Invited Speaker - Academic Health Sciences Leadership Program – “How to be politically Savvy”, Ottawa, Ontario, November 11, 2005.
55. Participated in Roundtable on Music and Medicine, “Music, Stroke and Recovery”, Ottawa, October 1, 2005.
56. Invited speaker, “Cardiovascular Diseases: Regional and Ethnic Profiles”, The 6th International Conference on Preventive Cardiology, Brazil, May 22, 2005.
57. Lecture “The Canadian Stroke Network, Goals, Function, Impact” to the NINDS/CSN/NHLBI Workshop, Washington DC, March 10-11, 2005
58. Co-Chair, NINDS/CSN/NHLBI Workshop, Washington DC, March 10-11, 2005
59. Invited speaker to the Canadian Stroke Research Innovation 7th Annual Stroke Collaborative, October 18, 2004.
60. Invited speaker, Presentation to the Board of the Canadian Stroke Consortium, Calgary, AB. October 16, 2004.
61. Invited speaker, Centre for Stroke Recovery. Presentation to Board Members of the Heart & Stroke Foundation of Ontario, Toronto, September 23, 2004.
62. Invited speaker, “Managing Strokes Everyday”, Cornwall, ON, September 22, 2004.
63. Invited speaker, Atlantic Research Symposium, Halifax “Opportunities for Stroke Research within the Canadian Stroke Network”, September 16, 2004,
64. "Go Home and Go Big" - National Strategies for Stroke" Symposium presented at World Stroke Congress - Vancouver - June 2004.
65. Invited speaker to European Stroke Conference, “Canadian Stroke Strategy” Mannheim, Germany, May 15, 2004.
66. Invited speaker to European Stroke Conference, “Gene Therapy in Stroke: Lessons from Past Trials”: Mannheim, Germany, May 13, 2004
67. Invited speaker to the Canadian Institutes of Health Research, “Toward a Canadian Stroke Strategy”, Ottawa, ON, April 14, 2004.
68. Invited speaker to the 24th Princeton Conference on Cerebrovascular Disease, “Conditioning the Brain. A Useful Paradigm for Neuroprotection?” and Moderator of session on “Ischemic Preconditioning”, Baltimore, MD, April 2 – 4, 2004.

69. Invited speaker to the Leon Wolfe Symposium, Montreal Neurological Institute, Montreal, QC, on "Conditioning the Brain" March 25, 2004.
70. Invited speaker to the MS Forum 2004, Lake Como, Italy "Neuroprotection in Acute and Chronic Disease. Lessons from Clinical Trials in Stroke". March 20, 2004.
71. Announced the results of a National Stroke Survey, conducted in partnership with Merck Frosst, to determine awareness levels in Canada about stroke risk factors. Conducted extensive media interviews and findings received coverage in more than 120 media outlets in December 2003 and January 2004.
72. Moderator of Session at BioNorth on "Neurosciences: Degeneration and Regeneration". Ottawa ON, November 18, 2003.
73. Invited speaker on Stroke Strategy, Atlantic Stroke Summit, Halifax, NS, October 15, 2003.
74. Invited speaker - Pfizer / CSN and Aventis/CSN – Partnerships, September 30, 2003.
75. Invited speaker on Stroke Recovery - March of Dimes – Annual General Meeting, Toronto, September 18, 2003.
76. Invited speaker on "Conditioning the Brain - Mechanisms of Increased Brain Resistance to Ischemic Damage", BRAIN 03, Calgary, July 3, 2003.
77. Invited speaker to CSN Partnerships Merck Frosst – Montreal, September 2, 2003.
78. Invited speaker for the Canadian Stroke Network Overview Presentation to Ministry of Health, June 11, 2003.
79. Invited speaker, Queens University, Kingston, Ontario "Conditioning the Brain, Mechanisms of Increased Brain Resistance to Ischemic Damage" May 1, 2003.
80. Invited speaker, Boehringer Ingelheim "Canadian Stroke Network/Partnerships" February 18, 2003.
81. Invited speaker, Institute of Neurology, Mental Health and Addiction, February 6, 2003.
82. Invited speaker, Neuroscience Canada Board Meeting, Montreal, Quebec. "Brain Recovery". October 1, 2002.
83. Invited speaker, Institute Advisory Board meeting of the Institute of Circulatory and Respiratory Health, Toronto, ON. September 19, 2002.
84. Invited speaker, Yarmouth Stroke Forum, Yarmouth, NS. "Stroke" September 4, 2002.
85. Invited speaker, Canadian Stroke Network Theme IVB meeting, London, ON, "Update on the CSN", May 31, 2002.
86. Invited speaker, for Eli Lilly Pharmaceutical, Indianapolis, Indiana, "The Challenges of Recovery After Stroke", May 22, 2002.
87. Keynote speaker for the Heart and Stroke Foundation of Ontario – 50 Years of Success "Stroke Happens to Families" Ottawa, May 9, 2002
88. Annual General Meeting of the Canadian Stroke Consortium, "Update on the Canadian Stroke Network", Toronto, May 3, 2002
89. Presentation to the Heart and Stroke Foundation of Ontario, Ottawa, February. 14, 2002
90. International Stroke Liaison Committee, San Antonio, Texas, "Canadian Stroke Network", February. 7, 2002
91. Lecture to the New Frontiers Meeting, San Antonio, Texas "Development of a rodent stroke recovery model". February 6, 2002
92. Lecture to the Stem Cell Network "Plasticity Workshop" - Vancouver, BC, January. 19, 2002
93. Presentation to the Research & Policy Committee of Heart & Stroke Foundation of Ontario, December 17, 2001
94. Lecture, Neurology Day, McGill University, Dept. of Neurology and Neurosurgery, "Research and Management in Stroke: Painful Realities and Great Hopes" April 5, 2001
95. Presentation to the Heart & Stroke Foundation of Ontario Board – Canadian Stroke Network, Toronto, Ontario August 23, 2001
96. Lecture to special group from Taiwan, and the NRC Conference on Mitochondrial Disease "Clinical Challenges in Stroke", Hull, Quebec, July 9, 2001.
97. Lecture - Ottawa Life Sciences - Lunch Time at the Park series: "The Canadian Stroke Network", May 4, 2001.
98. Lecture - Stroke symposium, "What does pathophysiology tell us about repair in cerebral ischemia?" Niagara-on-the-Lake, Ontario, April 6, 2001.

99. Lecture - Queens University, Kingston, Ontario, "Changing Perspectives", November 15, 2000.
100. Lecture to the Heart & Stroke Foundation of New Brunswick Provincial Stroke Conference, Saint John, NB, "Emerging Acute Stroke Therapies", September 22, 2000.
101. Lecture at the Institute for Clinical Evaluative Sciences, - Toronto, Ontario, "The Canadian Stroke Network", June 15, 2000
102. Lecture - Canadian Congress of Neurological Sciences, "Cerebral Ischemia: Pathophysiology", June 13, 2000
103. Invited lecturer as the Canadian representative - International Congress of the French Neurological Society, Paris, France, June 17, 18, 1999.
104. Participated in the 2nd Collaborative Forum on "Coordinated Stroke Strategy", Toronto, May 31, 1999.
105. Invited lecturer - Symposium on "Treatment of Acute Stroke and Secondary Prevention" 3rd Congress of the European Federation of the Neurological Societies, Seville, Spain, Sept. 1998.
106. Invited to address the Hungarian Stroke Society, 1997 and 1998 - declined
107. Invited speaker - Jerzy Olszewski lecturer - "Current Concepts and Future Prospects in Cerebral Ischemia and Stroke", Canadian Association of Neuropathologists, October 25, 1997.
108. Invited speaker - "Ischemic Penumbra: The Therapeutic Window", 2nd Annual Advances in Stroke Management, Cancun, Mexico, September 21, 1997.
109. Invited speaker - "Neuroprotection in ischemia", Neuroscience Rounds, Queen's University, May 15, 1997.
110. Invited speaker - "The stroke patient: Opportunities and challenges", Medical Grand Rounds, Queen's University, May 15, 1997.
111. "The Pathophysiology of Stroke", Emergency Medicine Task Force, Sainte-Adele, Quebec, February 1997.
112. Lecture - Acute Stroke Management - The Brain Attack Paradigm, Montreal, Quebec, September 28, 1996
113. "Improve your Awareness of Stroke", Women's Health Matters, September 1996
114. Invited lecturer - "The potential for neuroprotection in ischemia", Montreal Neurological Institute, September 1996.
115. Invited to Participate - Princeton Research Conference, 1996.
116. Invited to organize and chair "Molecular Biology of Ischemic Damage" - symposium for the 19th International Joint Conference on Stroke and Cerebral Circulation, The American Heart Association, San Diego, CA, February 17-19, 1994.
117. Invited to organize and chair "Role of Nitric Oxide in Cerebral Ischemia" - symposium for the 18th International Joint Conference on Stroke and Cerebral Circulation, The American Heart Association, Miami Beach, Florida, February 11-13, 1993.
118. Invited lecturer - "From Bench to Bedside" series - McGill University, April 1992.
119. Invited to organize and chair "Reversibility in Cerebral Ischemia" - symposium for the 17th International Joint Conference on Stroke and Cerebral Circulation, The American Heart Association, Phoenix, Arizona, January 30 to February 1, 1992.
120. Invited lecturer - "Stroke and Its Prevention", The Canadian Stroke Society, Halifax, NS, June 22, 1991.
121. Invited lecturer - "Cerebral Ischemia: From Pathophysiology to Treatment", Istanbul, Turkey, October 1990.
122. Invited lecturer - Satellite symposium of the XIth International Congress of Pharmacology, titled "Drug Treatment of Stroke and Ischemic Brain", Amsterdam, The Netherlands, June 1990.
123. Invited lecturer - Excitatory Amino Acid Receptors in the Brain: Functions and Disorders, Montreal, Quebec, June 1990.
124. Invited lecturer - Deidesheim Gesprach 1990, Cologne, West Germany, April 1990.
125. Invited lecturer - Preclinical Studies with Nimodipine Workshop, Scottsdale, Arizona, March 1990.

TEACHING ACTIVITY (selected)

1. Invited to Speak The Ottawa Hospital – Resident Research Day, October 12, 2010.
2. Invited to speak to University of Ottawa Medical Students, February 3, 2010. Title: Stroke and Its Impact.
3. Invited to speak at Rounds at the Montreal Neurological Institute, Montreal, Quebec, January 8, 2010. Title: Progress and Challenges in Stroke Prevention and Treatment.
4. Invited to speak – Rounds, The Ottawa Hospital, October 23, 2009. Lecture Title: STROKE More Scary than You Thought.....but preventable.
5. Invited Speaker - Invited Speaker – Title: Stroke and Its Impact – Medical Student Interest Group in Neurology (SIGN) at the University of Ottawa, November 5, 2008.
6. Invited Speaker at the Division of Neurology Grand Rounds, "The Contribution of Restful Sleep to Stroke Recovery", The Ottawa Hospital, June 23, 2006
7. Annually Participates in teaching Neuroscience Graduate Course, University of Ottawa, Course No. NSC 8106 - since 2000
8. "Stroke", Neurology Teaching Sessions, University of Ottawa Medical School, annually since 2000.
9. Participation at Scientific Meetings Canadian Congress of Neurology - Neurobiology Review – Stroke Prevention, Ottawa, June 18, 2005
10. Invited speaker, "Ischemic Cascades" at the Neurology Half-days The Ottawa Hospital, November 9, 2004
11. Invited speaker to the Neurosurgery Rounds, "Clinical Challenges in Stroke", The Ottawa Hospital, Civic Campus, Ottawa, ON March 5, 2004.
12. Invited speaker at the Stroke Book Club, "Inventing a brighter future for stroke patients and their families", Ottawa ON, March 2, 2004.
13. Invited speaker at the Division of Neurology Grand Rounds, "Conditioning the Brain: Mechanisms of Increased Brain Resistance to Ischemic Damage", The Ottawa Hospital, May 16, 2003.
14. Neuroscience Seminar Series "Conditioning" the Brain. What Mechanisms Contribute to Making it More Resistant to Ischemic Damage?" April 14, 2003.
15. Invited speaker, BioNorth "Principles of Brain Plasticity Should Guide Clinical Interventions after Stroke" November 6, 2002
16. Invited speaker, Westend Learning Unlimited, Ottawa, Ontario. "Stroke", October 29, 2002.
17. Lecture - Hospital Auxiliaries Association of Ontario, "Recent Developments in the Treatment of and Research into Strokes", Ottawa, October 20, 1999.
18. Invited speaker - "Damage and recovery in cerebral ischemia", Department of Cellular and molecular Medicine, University of Ottawa, June 30, 1998.
19. Invited speaker - "The Stroke Network: A Network of Centres of Excellence in Stroke", Neuroradiology/Neurology/Neurosurgery Rounds, Ottawa Hospital - General Campus, February 27, 1998.
20. Invited speaker - "Brain Attacks - Emergency Management", Annual Refresher Course for Family Practitioners and other Health Care Professionals, Ottawa General Hospital, December 5, 1997.
21. Neurology tutor, Physicians Skills Development, Neuroblock for second-year medical students, University of Ottawa, 1997.
22. Rounds speaker, "The potential for neuroprotection in ischemia", Ottawa General Hospital Neurology Rounds, 1997.
23. "Invited speaker - "Cell death in ischemia and potential for neuroprotection", Department of Biochemistry, University of Ottawa, January 17, 1997.
24. Lecture - "Stroke Management" - Regional Heart Saver Committee of Ottawa-Carleton, November 23, 1996.
25. Current Clinical Trials in Stroke ", Neurology teaching sessions, University of Ottawa Medical School, April 4, 1995.
26. Cerebrovascular Disease ", Continuing Medical Education University of Ottawa, 1994
27. Ad hoc examiner for neurology trainees, University of Ottawa, 1993-1997.
28. Attending staff neurologist on neurology service, with two-three residents - The Ottawa Hospital, 1992-2002.

29. Organizer, Seminars in Brain Imaging Research, Montreal Neurological Institute, 1990.
30. "Brain Ischemia", Neurosurgery teaching sessions, McGill University, 1988.
31. "Headaches", Neurology for Non-Neurologists, Continuing Medical Education, McGill University, 1986.
32. "Metabolism of brain before, during and after a stroke", Seminars on Atherosclerosis, Thrombosis and their Complications, McGill University, 1985-1987.
33. "Syncope", Neurology for Non-Neurologists, Continuing Medical Education, McGill University, 1985.
34. Responsible for "Link" students during their second year of medical school - one month per year, McGill University, 1985-1992.
35. "Biology of Disease" - Lectured with Drs. L. Wolfe and H. Pappius, second year medical students, McGill University, 1984-1986.
36. "Metabolic Encephalopathies", lecturer and organizer of series, Neuroscience seminars, McGill University, 1985.
37. "Neurology of Dementia", Neuropsychiatry Seminars, McGill University, 1984-1985.
38. "Cerebrovascular Accidents", School of Physical and Occupational Therapy, Neurology Lecture Series, McGill University, 1984-1985
39. "Cerebrovascular Diseases", Thursday evening lecture series, McGill University, 1984.
40. Frequent speaker and discussant at Grand Rounds at Montreal Neurological Institute, Royal Victoria Hospital and Montreal General Hospital, 1980-1990.
41. Attending staff neurologist on neurology service "C", Montreal Neurological Institute in charge of approximately twenty patients during January and February for each year. This entailed considerable teaching of residents, McGill University, 1979-1992.

OTHER CONTRIBUTIONS

- a) Editorial Boards
 - STROKE, 2000 to 2006
 - Member, Board of Directors, Canadian Medical Association Journal, 1999 – 2002.
 - Board Member, Strokeline: Support for Survivors and Caregivers, a publication of the Heart and Stroke Foundation of Canada
- b) Journals

Ad Hoc Reviewer for:

 - American Journal of Physiology
 - Annals of Neurology
 - Canadian Medical Association Journal
 - CNS Drug Reviews
 - Journal of Cerebral Blood Flow and Metabolism
 - Journal of Neurochemistry
 - Stroke

COMMITTEES

CURRENT

Ottawa Hospital Committees -

- Ottawa Health Research Institute - Senior Management Team
- Department of Medicine Joint Division Heads Committee

Division of Neurology Committees

- Recruitment Committee

Canadian Stroke Network

- Board of Directors
- Management Committee
- Planning and Priorities Committee
- External Scientific Review Committee
- Audit and Finance Committee
- Executive Committee

Canadian Stroke Strategy

- Steering Committee
- Best Practices Committee

Heart and Stroke Foundation Centre for Stroke Recovery

- Advisory Board
- External Scientific Review Committee
- Site Leaders' Committee
- Scientific Committee

OTHER

- Member - NCE Directors Committee
- Chair - Phoenix BioPharm External Scientific Selection Committee, Chair
- Board Member - International Advisory Committee for 6th World Stroke Congress - 2008
- Board Member - Canadian Heart Health Strategy and Action Plan Steering Committee
- Chair - Scientific Advisory Board, European Stroke Network
- Chair - World Stroke Organization International Stroke Guidelines Sub-Committee
- Board Member - World Stroke Organization - Advisory Board
- Member - World Stroke Organization - Executive Committee
- Board Member - FRSQ

PAST

University of Ottawa Committees

- Neuroscience Research Institute Advisory Board
- Neuroscience Research Institute External Scientific Committee

Canadian Institutes for Health Research

- Institute Advisory Board, Institute for Circulatory and Respiratory Health, 2001-2004
- Stroke Summit Committee, November 2003
- AstraZeneca Neurology Advisory Board

PROFESSIONAL SOCIETIES

1. American Academy of Neurology
2. American Association for the Advancement of Science
3. American Heart Association
4. American Neurological Association
5. American Society for Neurochemistry
6. Canadian Institute of Academic Medicine
7. Canadian Neurological Society
8. Canadian Stroke Society
9. Society for Neuroscience

RESEARCH AWARDS

Research Grants

A) INSTITUTIONAL

Heart and Stroke Foundation of Ontario and Matching Funds

Centre of Excellence – Heart and Stroke Foundation Centre for Stroke Recovery

Scientific Director

2001 – 2011 **\$12,000,000**

Additional fundraising goal set in 2005 **\$25,000,000**

Achieved to Date **\$25,000,000**

Goal raised to \$40,000,000

Networks of Centres of Excellence Program -

Network of Centres of Excellence for the Canadian Stroke Network (CSN)

CEO and Scientific Director, Dr. Antoine M. Hakim

Network grant with 145 investigators from across Canada

2000 - 2006 **\$32,900,000**

2006 – 2013 **\$44,800,000**

Support of the infrastructure of the OSCAR program grant (T-3551) - Ottawa Stroke Consortium for Applied Research (OSCAR) - Group Grant with 16 other investigators

Total Grant - \$1 237 357 (July 1, 1997 - June 30, 2000) **\$1,237,357**

B) INDIVIDUAL

Canadian Stroke Network - Mobilization of Neural Stem Cells Following Stroke

Principal Investigator: A. Hakim, with Dr. Luc Sabourin

2002-2003 **\$55,000/yr**

Networks of Centres of Excellence

Post-Stroke Recovery Can be Modulated by Manipulating Calcium and NMDA Homeostasis During The Repair Phase

2000 - 2003 **\$60,000**

Networks of Centres of Excellence

Understanding the Molecular Basis of Neuroprotection; Gene Expression Analyses in Dying Neurons (in vitro and *in vivo*) Using DNA Chip Arrays and Differential Display

2000 - 2003 **\$30,000**

Heart and Stroke Foundation of Ontario

Molecular Mechanisms of Neuroprotection – with Dr. Luc Sabourin

2003- 2005 (NA-5084) **\$106,000**

Role of XIAP in calcium ion homeostasis - (part of the OSCAR program) - with Dr. Charlie Thompson (NA-4373)

2000 - 2002 **\$62,000/yr**

The molecular basis of cerebral plasticity - with Dr. Andre Douen (B-3624)

1998 - 1999 **\$51,365**

1999 - 2000 **\$51,586**

The ischemic penumbra dies by apoptosis (NA-3623)

1998 - 2000 **\$58,680/yr**

Effect of modulation of calcium homeostasis on ischemic neuroprotection - (part of the OSCAR program) - with Dr. Matthew J. Hogan (PI), and Dr. Paul Morley (T-3379)

1997 - 1998	\$45,267
1998 - 1999	\$46,172
1999 - 2000	\$47,096

Seed money for "MRI project" (within the Infrastructure support of OSCAR program grant) with Drs. Matthew J. Hogan, Diana M. Grinnell, Brian E. Heisel and Leonard I. Avruch (part of T-3551)

1997 - 1998	\$25,000
--------------------	-----------------

CNS plasticity: its molecular substrates and its modulation (B-3068)

1996 - 1998	\$48,169/yr
--------------------	--------------------

Modalities of cellular injury, protection and treatment of stroke (Infrastructure support) (ST-2719)

Ottawa Stroke Consortium for Applied Research (OSCAR) - Group Grant with 17 other investigators

Total Grant - \$826 872 (July 1, 1995 - June 30, 1997)

1995 - 1997	\$56,000/yr
--------------------	--------------------

Calcium channel activation, trophic factors and neuroprotection - with Dr. Matthew Hogan (PI), and Dr. Rainald Schmidt-Kastner (ST-2721)

1995 - 1996	\$46,654
--------------------	-----------------

1996 - 1997	\$49,466
--------------------	-----------------

Neurotrophins in cerebral ischemia: expression and therapeutic potential - with Dr. Rainald Schmidt-Kastner (NA-2867)

1995 - 1996	\$64,260
--------------------	-----------------

1996 - 1997	\$57,760
--------------------	-----------------

Induction and function of immediate early genes in cerebral ischemia - with Dr. George S. Robertson (B-2568)

1994 - 1996	\$66,272/yr
--------------------	--------------------

Nimodipine binding in cerebral ischemia

1992 - 1993	\$45,397
--------------------	-----------------

1993 - 1994	\$48,018
--------------------	-----------------

London Life Medical Research Award - Improving the brain's resistance to stroke damage - with Drs. Matthew J. Hogan, Rainald Schmidt-Kastner and George S. Robertson

1994 - 1996	\$100,000/yr
--------------------	---------------------

Miles Pharmaceuticals - Immediate early genes in focal ischemia

1993 - 1995	\$16,000/yr
--------------------	--------------------

Medical Research Council

Determinants of tissue survival in two models of selective vulnerability (MT-8789)

1992 - 1994	\$64,605/yr
--------------------	--------------------

1994 - 1995	\$16,151
--------------------	-----------------

Calcium channel activity in two models of selective cerebral vulnerability

1989 - 1990	\$42,423
--------------------	-----------------

1990 - 1992	\$56,565/yr
--------------------	--------------------

Coordinator of Program Grant to PET Research		
1987 - 1990		\$300,000/yr
1987 - 1989	Towards the acquisition of a new tomograph	\$1,000,000
Cerebral acidosis and other metabolic functions in models of focal brain damage		
1984 - 1985		\$30,186
1985 - 1986		\$40,852
1986 - 1987		\$52,817
1987 - 1989		\$57,007/yr
Ciba-Geigy Canada Ltd. -		
Measurement of kinetic and physiologic properties of two NMDA-receptor antagonists in normal and ischemic brain		
1992 - 1994		\$107,396/yr
Nordic Laboratories Inc.		
Binding of TA-3090 in normal and ischemic brain		
1990 - 1991		\$86,918
National Institutes of Health		
Calcium channel activation in models of cerebral ischemia		
1989 - 1990		\$64,478
1990 - 1991		\$75,478
University-Industry Collaborative Grant		
NMDA-receptor function and blockade in cerebral ischemia (using CGS-19755 as a prototype)		
1989 - 1990		\$67,000
1990 - 1991		\$38,000
Quebec Heart Foundation Grant-In-Aid		
1986 - 1988	Cerebral acidosis in ischemia	\$17,000/yr
1988 - 1991	Cerebral metabolic responses to stroke and therapy	\$25,000/yr
Juvenile Diabetes Foundation		
Cerebrovascular function and responsiveness in diabetes studied by positron emission tomography and magnetic resonance imaging		
1985 - 1987		\$33,000/yr
Canadian Heart Foundation		
1984 - 1990	Research Scholarship	\$35,000/yr
Heart and Stroke Foundation of Canada - Scholarship - Source of salary support.		
1984 - 1990		\$42,650/yr av.

PUBLICATIONS

- * Identifies peer-reviewed articles where the applicant's scientific contribution was major.
- ** Identifies peer-reviewed articles where the applicant's scientific contribution was important but not major.
- *** Show manuscripts where the applicant contributed to the study at various stages which may have involved, when appropriate, discussing and approving details of the study, preparing ethics committee proposal and defending it, identifying patients for study or analysis, being on call during the study, funding the study, supervising data collection and analysis, reading the manuscript and advising main authors until its publication.
1. Endres M, Heuschmann PU, Laufs U, **Hakim A**. *Frontiers in cardiovascular medicine* "Primary prevention of stroke: Blood pressure, lipids and heart failure". Invited Comprehensive Clinical Review Article for the European Heart Journal (EHJ). Accepted October 2010.*
 2. Sharma M, **Hakim A**. The Management of Hypertension for Primary Stroke Prevention: A proposed Approach. *International Journal of Stroke*. Accepted August 2010.*
 3. Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, Fisher M, Brainin M, Buchan AM, Lo EH, Skolnick BE, Furie KL, Hankey GJ, Kivipelto M, Morris J, Rothwell PM, Sacco RL, Smith SC Jr, Wang Y, Bryer A, Ford GA, Iadecola C, Martins SC, Saver J, Skvortsova V, Bayley M, Bednar MM, Duncan P, Enney L, Finklestein S, Jones TA, Kalra L, Kleim J, Nitkin R, Teasell R, Weiller C, Desai B, Goldberg MP, Heiss WD, Saarelma O, Schwamm LH, Shinohara Y, Trivedi B, Wahlgren N, Wong LK, **Hakim A**, Norrving B, Prudhomme S, Bornstein NM, Davis SM, Goldstein LB, Leys D, Tuomilehto J., Department of Clinical Neurological Sciences, London Health Sciences Center, University of Western Ontario, and St. Joseph's Healthcare London, London, Ont., USA.. *Stroke: Working toward a Prioritized World Agenda. Cerebrovasc Dis.* 2010 May 24;30(2):127-147.**
 4. Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, Fisher M, Brainin M, Buchan AM, Lo EH, Skolnick BE, Furie KL, Hankey GJ, Kivipelto M, Morris J, Rothwell PM, Sacco RL, Smith SC Jr, Wang Y, Bryer A, Ford GA, Iadecola C, Martins SC, Saver J, Skvortsova V, Bayley M, Bednar MM, Duncan P, Enney L, Finklestein S, Jones TA, Kalra L, Kleim J, Nitkin R, Teasell R, Weiller C, Desai B, Goldberg MP, Heiss WD, Saarelma O, Schwamm LH, Shinohara Y, Trivedi B, Wahlgren N, Wong LK, **Hakim AM**, Norrving B, Prudhomme S, Bornstein NM, Davis SM, Goldstein LB, Leys D, Tuomilehto J. *stroke: Working toward a Prioritized World Agenda. Stroke.* 2010 Jun;41(6):1084-99. Review**
 5. Saposnik G, Black S, **Hakim A**, Fang J, Tu J and Kapral M. Age disparities in Stroke Quality of Care and Delivery of Health Services. *Stroke.* 2009 Oct;40(10):3328-35.**
 6. Dowlatshahi D, **Hakim A**, Fang J, Sharma M. Pre-admission antithrombotics are associated with improved outcomes following ischemic stroke: a cohort from the Registry of the Canadian Stroke Network. *International Journal of Stroke*, October 2009,4: 328–334.**
 7. Charron C, Schock S, Proulx G, Thompson C, **Hakim A**, Plamondon H. Protection conferred by Corticotropin-releasing hormone in rat primary cortical neurons against chemical ischemia involves opioid receptor activation. *Brain Research.*2009 Feb 27 1257: 117-127.**
 8. Thompson C and **Hakim A**. Living Beyond Our Physiological Means: Small Vessel Disease Of The Brain Is An Expression Of A Systemic Failure In Arteriolar Function. A Unifying Hypothesis. *Stroke* 2009 May; 40 (5): E 322-30.*
 9. **Hakim A** and Thompson C. Gene Induction, Protein Synthesis and Related Issues. *Handbook of Clinical Neurology.* 2008; 92:137-47.*
 10. Schock, SC, LeBlanc D, **Hakim AM**, Thompson CS. ATP release by way of connexin 36 hemichannels mediates ischemic tolerance in vitro. *Biochem Biophys Res Comm.* 2008 Mar. 368 (1): 138-144.**
 11. **Hakim AM**, *Vascular Disease: The Tsunami of Health Care - The 2007 Willis Lecture. Stroke.* 2007 Dec. 38 (12) 0039-2499. *
 12. Schock SC, Munyao N, Yakubchuk Y, Sabourin L, **Hakim AM**, Ventureyra ECG, Thompson CS. Cortical spreading depression releases ATP into the extracellular space and purinergic receptor activation contributes to the induction of ischemic tolerance. *Brain Res.* 2007 Sep 7, 1168C: 129-138. *

13. Hester I, McKee S, Pelletier P, Thompson C, Storbeck C, Mears A, Schulz JB, **Hakim AM**, Sabourin L. Transient expression of Nxf, a bHLH-PAS transactivator Induced by neuronal preconditioning, confers neuroprotection in cultured cells. *Brain Res.* 2007 Mar 2; 1135(1):1–11. **
14. Hallenbeck J, Del Zoppo G, Jacobs T, **Hakim AM**, Goldman S, Utz U, Hasan A. Immunomodulation Workshop Participants. Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary. *Stroke.* 2006 Dec; 37 (12): 3035-42. **
15. McKee SC, Thompson CS, Sabourin LA, **Hakim AM**. Regulation of Expression of Early Growth Response Transcription Factors in Rat Primary Cortical Neurons by Extracellular ATP. *Molecular Brain Research.* 2006 May 9; 1088 (1): 1-11. **
16. Dowlatshahi D, Fang J, Kawaja M, **Hakim AM**. Use of calcium channel blockers after stroke is not associated with poor outcome: A cohort from the registry of the Canadian Stroke Network. *J. Neurol.* 2006 Nov; 253 (11): 1478-83. **
17. Thompson CS, **Hakim AM**: Cortical Spreading Depression Modifies Components of the Inflammatory Cascade. *Molecular Neurobiology* 32: 51-57., 2005. *
18. **Hakim AM**, Simon R: Ischemic Preconditioning, Introduction. *Stroke*, 35(suppl 1) 2675, 2004. **
19. D, Walker JR, Thompson CS, Moroz I, Lin W, Veselits MS, **Hakim AM**, Fienberg AA, Thinakaran G. Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. *Molecular & Cellular Biology*, 24:21, 9456-9469, 2004. **
20. Moroz IA, Kreling K, Thompson CS, **Hakim AM**: Effects of d-amphetamine on long-term functional outcome after middle cerebral artery occlusion in the rat. *Society for Neuroscience Abstracts*, 30, 807.7, 2004. **
21. Douen AG, Dong L, Vanance S, Munger R, Hogan MJ, Thompson CS, **Hakim AM**: Regulation of nestin expression after cortical ablation in adult rat brain. *Brain Research*, 1008: 139-146, 2004. **
22. Gulyaeva N, Thompson C, Shinohara N, Lazareva N, Onufriev M, Stepanichev M, Moiseeva Y, Fliss H, **Hakim AM**: Tongue Protrusion: A Simple Test for Neurological Recovery in Rats Following Focal Cerebral Ischemia. *The Journal of Neuroscience Methods*, 125 (1-2): 183-193, 2003. *
23. Kametsu Y, Osuga S, **Hakim AM**. Apoptosis occurs in the penumbra zone during short duration focal ischemia in the rat. *J. Cereb. Blood Flow & Metab.* 23:416-422, 2003. *
24. Gladstone D, Black S, **Hakim AM**. Toward Wisdom from Failure: Lessons Learned from Negative Stroke Treatment Trials and New Therapeutic Frontiers *Stroke* 33:2123-2136, 2002.*
25. Chow AK, Thompson CS, Hogan MJ, Banner D, Sabourin LA, **Hakim AM**: Cortical spreading depression transiently activates MAP kinases. *Molecular Brain Research* 99:75-81, 2002. *
26. Gendron TF, Mealing GAR, Paris J, Lou A, Edwards A, Hou ST, MacManus JP, **Hakim AM**, Morley P: Attenuation of neurotoxicity in cortical cultures and hippocampal slices from E2F1 knockout mice, *Journal of Neurochemistry*, 78: 316-324, 2001. ***
27. Zhang, YH, Hume K, Cadonic R, Thompson C, **Hakim AM**: Expression profile and activity of the Ste20-like kinase SLK in the embryonic and adult nervous system. *Brain Res Dev Brain res* 139(2):205-15, 2002. **
28. Wang F, Corbett D, Osuga H, Osuga S, Ikeda J, Slack RS, Hogan MJ, **Hakim AM** and Park DS: Inhibition of cyclin dependent kinases provides improvements in CA1 neuronal survival and behavioural performance after global ischemia in the rat. *J. Cereb. Blood Flow & Metab.* 22(2): 171-182, 2002. **
29. Fortin A, Cregan, SP, MacLaurin JG, Kushwaha N, Hickman, ES, Thompson CS, **Hakim AM**, Albert PR, Cecconi F, Helin K, Park DS, and Slack RS. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. 2001, *Journal of Cell Biology.* 155(2): 207-216, 2001. **
30. Osuga H, Osuga S, Wang F, Fetni R, Hogan MJ, Slack RS, **Hakim AM**, Ikeda J and Park DS. Cyclin-dependent kinases as a therapeutic target for stroke. *Proc Natl Acad Sci USA* 97:18 10254-10259, 2000. **

31. Douen AG, Akiyama K, Hogan MJ, Wang F, Dong L, Chow AK and **Hakim AM**. Preconditioning with cortical spreading depression decreases intra-ischemic cerebral glutamate levels and down regulates EAAT1 and EAAT2 from rat cerebral cortex plasma membranes. *Journal of Neurochemistry* 75/2: 812-818, 2000. **
32. Tauskela JS, Hewitt K, Kang LP, Comas T, Gendron T, **Hakim AM**, Hogan M, Durkin J and Morley P. Evaluation of glutathione-sensitive fluorescent dyes in cortical cultures. *Glia* 30: 329-341, 2000. ***
33. **Hakim AM**: Physiologie et pathologie de l'ischémie cérébrale. *Revue Neurologique* 155: 9: 631-637, 1999. *
34. Tauskela J, Chakravarthy BR, Murray C, Wang Y, Comas T, Hogan MJ, **Hakim AM** and Morley P. Evidence from cultured rat cortical neurons of differences in the mechanism of ischemic preconditioning of brain and heart. *Brain Res* 827: 143-151, 1999. ***
35. McGahan L, **Hakim AM** and Robertson GS: Hippocampal Myc and p53 expression following transient global ischemia. *Molecular Brain Research*, 56(1-2): 133-145, 1998.**
36. McGahan L, **Hakim AM**, Nakabeppu Y and Robertson GS: Ischemia-induced CA1 neuronal death is preceded by elevated FosB and Jun expression and reduced NGFI-A and JunB levels. *Molecular Brain Research*, 56(1-2): 146-161 1998.**
37. Skljarevski V, Turek M and **Hakim AM**: Cervical artery dissection is associated with widened aortic root diameter. *Can J Neurol Sci* 25: 315-319, 1998.*
38. Douen AG and **Hakim AM**: Physiopathologie de l'ischémie cérébrale. In: *Revue: Accidents vasculaires cérébraux de l'adulte*, P Aubourg and JL Maas (Eds), *Medecine Therapeutique*, John Libbey, Montrouge, France. Vol 4: 435-441, 1998.
39. Matsushima K, Schmidt-Kastner R, Hogan MJ and **Hakim AM**: Cortical spreading depression activates trophic factor expression in neurons and astrocytes and protects against subsequent focal brain ischemia. *Brain Res* 807: 47-60, 1998.*
40. Tauskela JS, Mealing G, Jacobson SL, **Hakim AM** and Morley P: A regulated environmental perfusion system for the study of anoxic or hypoxic cultured neurons using micro fluorescence imaging and electrophysiology. *Pflugers Arch - Eur J Physiol* 435: 775-780, 1998. ***
41. **Hakim AM**, Silver F and Hodgson C. Organized stroke care: A new era in stroke prevention and treatment. *CMAJ* 159: 1-S, September 1998.
42. Hazell AS, **Hakim AM**, Senterman MK and Hogan MJ: Regional activation of L-type voltage-sensitive calcium channels in experimental thiamine deficiency. *J Neurosci Res* 52: 742-749, 1998.*
43. Hazell AS, McGahan L, Tetzlaff W, Bedard AM, Robertson GS, Nakabeppu Y and **Hakim AM**: Immediate-early gene expression in the brain of the thiamine-deficient rat. *J Molec Neurosci* 10: 1-15, 1998.**
44. Duggal N, Schmidt-Kastner RS and **Hakim AM**: Nestin expression in reactive astrocytes following focal cerebral ischemia in rats. *Brain Res* 768: 1-9, 1997.*
45. Xu DG, Crocker SJ, Doucet J-P, St-Jean M, Tamai K, **Hakim AM**, Ikeda J-E, Liston P, Thompson CS, Korneluk RG, MacKenzie A and Robertson GS: Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. *Nature Med* 3: 997-1004, 1997.**
46. Xu DG, Korneluk RG, Tamai K, Wagle N, **Hakim AM**, MacKenzie A and Robertson GS: Distribution of neuronal apoptosis inhibitory protein-like immunoreactivity in the rat central nervous system. *J Comp Neurol* 382: 247-259, 1997. **
47. Schmidt-Kastner R, Bedard A and **Hakim AM**: Transient expression of GAP-43 within the hippocampus after global brain ischemia in rat. *Cell Tissue Res* 288: 225-238, 1997. **
48. Osuga S, **Hakim AM**, Osuga H and Hogan MJ: *In vivo* uptake of [3H]nimodipine into brain during cortical spreading depression. *J Cereb Blood Flow Metab* 17: 586-590, 1997. **
49. Matsushima K, MacManus JP and **Hakim AM**: Apoptosis is restricted to the thalamus in thiamine-deficient rats. *NeuroReport* 8: 867-870, 1997.*
50. Schmidt-Kastner R, Fliss H and **Hakim AM**: Subtle neuronal death in striatum after short forebrain ischemia in rats detected by in situ end-labelling for DNA damage. *Stroke* 28: 163-169, 1997.**

51. Matsushima K, Hogan MJ and **Hakim AM**: Cortical spreading depression protects against subsequent focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 16: 221-226, 1996.*
52. Osuga H and **Hakim AM**: Relationship between extracellular glutamate concentration and voltage-sensitive calcium channel function in focal cerebral ischemia in the rat. *J Cereb Blood Flow Metab* 16: 629-636, 1996.*
53. Hogan MJ, Takizawa S and **Hakim AM**: In vitro binding of [3H] nimodipine and [3H] CGS-19755 to rat brain in focal cerebral ischemia. *Exp Neurol* 134: 56-63, 1995.**
54. Matsushima K and **Hakim AM**: Transient forebrain ischemia protects against subsequent focal cerebral ischemia without changing cerebral perfusion. *Stroke* 26: 1047-1052, 1995.*
55. Osuga H and **Hakim AM**: Relevance of interstitial glutamate to selective vulnerability in focal cerebral ischemia. *J Cereb Blood Flow Metab* 14: 343-347, 1994.*
56. Takizawa S, Hogan MJ, Buchan AM and **Hakim AM**: *In vivo* binding of [3H] nimodipine in rat brain after transient forebrain ischemia. *J Cereb Blood Flow Metab* 14: 397-405, 1994.**
57. **Hakim AM**: Could transient ischemic attacks have a cerebroprotective role? *Stroke* 25: 715-717, 1994.*
58. Hogan MJ and **Hakim AM**: Nimodipine binding in cerebral ischemia: Response to therapy. *Drugs in Develop* 2: 325-335, 1993.**
59. Hazell AS, Butterworth RF and **Hakim AM**: Cerebral vulnerability is associated with selective increase in extracellular glutamate concentration in experimental thiamine deficiency. *J Neurochem* 61: 1155-1158, 1993. **
60. Hogan MJ and **Hakim AM**: Reversibility of nimodipine binding to brain in transient cerebral ischemia. *J Neurochem* 59: 1745-1752, 1992. **
61. **Hakim AM**, Hogan MJ and Carpenter S: Time course of cerebral blood flow and histological outcome after focal cerebral ischemia in rats. *Stroke* 23: 1138-1144, 1992.*
62. Hogan MJ, Gjedde A and **Hakim AM**: In-vivo distribution of CGS-19755 within brain in a model of focal cerebral ischemia. *J Neurochem* 58: 186-191, 1992.**
63. Meyer E, Delpla P, Petrides M, Ethier R, Bes A and **Hakim AM**: PET metabolic and neuropsychological correlates of periventricular lucencies. In: *Cerebral Ischemia and Dementia*, Hartmann, Kuschinsky, Hoyer (Eds), 368-373, 1991.
64. Takizawa S and **Hakim AM**: Animal Models of Cerebral Ischemia. 2. Rat Models. *Cerebrovasc Dis* 1(suppl 1): 16-21, 1991.*
65. Hogan MJ, Gjedde A and **Hakim AM**: *In vivo* binding of nimodipine in the brain. II. Binding kinetics in focal cerebral ischemia. *J Cereb Blood Flow Metab* 11: 771-778, 1991.*
66. **Hakim AM** and Hogan MJ: *In vivo* binding of nimodipine in the brain. I. The effect of focal cerebral ischemia. *J Cereb Blood Flow Metab* 11: 762-770, 1991.*
67. Takizawa S, Hogan M and **Hakim AM**: The effects of a competitive NMDA receptor antagonist (CGS-19755) on cerebral blood flow and pH in focal ischemia. *J Cereb Blood Flow Metab* 11: 786-793, 1991.*
68. Meyer E, Ferguson SS, Zatorre RJ, Alivisatos B, Marrett S, Evans AC and **Hakim AM**: Attention modulates somatosensory cerebral blood flow response to vibrotactile stimulation as measured by positron emission tomography. *Ann Neurol* 29: 440-443, 1991.
69. Archer DP, Labrecque P, Tyler JL, Meyer E, Evans AC, Villemure JC, Casey WF, Diksic M, **Hakim AM**, Trop D: Measurement of cerebral blood flow and volume with positron emission tomography during isoflurane administration in the hypocapnic baboon. *Anesthesiology* 72: 1031-1037, 1990.***
70. Hogan M, Gjedde A and **Hakim AM**: Nimodipine binding in focal cerebral ischemia. *Stroke* 21(Suppl IV): IV78-IV80, 1990.*
71. Gjedde A, Kuwabara H and **Hakim AM**: Reduction of functional capillary density in human brain after stroke. *J Cereb Blood Flow Metab* 10: 317-326, 1990.***
72. Dyve S, Gjedde A, Diksic M, Sherwin A and **Hakim AM**: *In vivo* quantification of blood-brain transfer and binding of [125I] HEAT, an α 1-adrenoceptor antagonist. *Synapse* 3: 205-212, 1989. ***
73. Tyler JL, Leblanc R, Meyer E, Dagher A, Yamamoto YL, Diksic M and **Hakim AM**: Hemodynamic and metabolic effects of cerebral arteriovenous malformations studied by positron emission tomography. *Stroke* 20: 890-898, 1989.***

74. Redies C, Hoffer LJ, Beil C, Marliss EB, Evans AC, Lariviere F, Marrett S, Meyer E, Diksic M, Gjedde A and **Hakim AM**: Generalized decrease in brain glucose metabolism during fasting in humans studied by PET. *Am J Physiol* 256: E805-E810, 1989.***
75. **Hakim AM**, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, Biel C, Pokrupa R, Diksic M, Meyer E, Gjedde A and Marrett S: The effect of nimodipine on the evolution of human cerebral infarction studied by PET. *J Cereb Blood Flow Metab* 9: 523-534, 1989.*
76. Berger L and **Hakim AM**: Nimodipine prevents hyperglycemia-induced cerebral acidosis in middle cerebral artery occluded rats. *J Cereb Blood Flow Metab* 9: 58-64, 1989.*
77. LeBlanc R, Yamamoto YL, Tyler JL and **Hakim AM**: Hemodynamic and metabolic effects of extracranial carotid disease. *Can J Neurol Sci* 16: 51-57, 1989.**
78. Matthews PM, Evans AC, Andermann F and **Hakim AM**: Regional cerebral glucose metabolism differs in the adult and rigid juvenile forms of Huntington disease. *Pediatr Neurol* 5: 353-356, 1989***
79. Berkovic SF, Carpenter S, Evans A, Karpati G, Shoubridge E, Andermann F, Meyer E, Tyler JL, Diksic M, Arnold DL, Wolfe LS, Andermann E and **Hakim AM**: Myoclonus epilepsy and ragged-red fibres (MERRF): 1. A clinical, pathological, biochemical, magnetic resonance spectrographic and positron emission tomographic study. *Brain* 112: 1231-1260, 1989**
80. Kitamura S, Yamamoto YL, **Hakim AM**, Evans A, Meyer E, Kato A and Pokrupa R: Patterns of physiological and biochemical changes in acute human cerebral infarction with and without hyperglycemia studied by positron emission tomography. *Am J Physiol Imag* 3: 50, 1988. **
81. Berger L and **Hakim AM**: Calcium channel blockers correct acidosis in ischemic rat brain without altering cerebral blood flow. *Stroke* 19: 1257-1261, 1988.*
82. Evans AC, Beil C, Marrett S, Thompson CJ and **Hakim AM**: Anatomical-functional correlation using an adjustable MRI-based region of interest atlas with positron emission tomography. *J Cereb Blood Flow Metab* 8: 513-530, 1988.**
83. Stewart DJ, Gelston A and **Hakim AM**: Effect of prophylactic administration of nimodipine in patients with migraine. *Headache* 28: 260-262, 1988.*
84. Vogel S and **Hakim AM**: Effect of nimodipine on the regional cerebral acidosis accompanying thiamine deficiency in the rat. *J Neurochem* 51: 1102-1110, 1988.*
85. Leblanc R, Tyler JL, Mohr G, Meyer E, Diksic M, Yamamoto L, Taylor L, Gauthier S, **Hakim AM**. Hemodynamic and metabolic effects of cerebral revascularization. *Neurosurg* 66: 529-535, 1987.**
86. Biller J, Brott TG, Coull BM, Davenport JG, Easton JD, Fisher M, Furlan AJ, **Hakim AM** et al.: Cardioembolic Stroke, Early Anticoagulation, and Brain Hemorrhage. Cerebral Embolism Study Group. *Arch Intern Med* 147: 636-640, 1987. **
87. Meyer E, Tyler JL, Thompson CJ, Redies C, Diksic M and **Hakim AM**: Estimation of cerebral oxygen utilization rate by single-bolus $^{15}O_2$ inhalation and dynamic positron emission tomography. *J Cereb Blood Flow Metab* 7: 403-414, 1987.***
88. Leblanc R, Yamamoto YL, Tyler JL, Diksic M and **Hakim AM**: Borderzone Ischemia. *Ann Neurol* 22: 707-713, 1987.**
89. **Hakim AM**, Pokrupa RP, Villanueva J, Diksic M, Evans AC, Thompson CJ, Meyer E, Yamamoto YL and Feindel WH: The effect of spontaneous reperfusion on metabolic function in early human cerebral infarcts. *Ann Neurol* 21: 279-289, 1987.*
90. Berger L and **Hakim AM**: The association of hyperglycemia with cerebral edema in stroke. *Stroke* 17: 865-871, 1986.*
91. **Hakim AM**: Cerebral acidosis in focal ischemia: II - Nimodipine and Verapamil normalize cerebral pH following middle cerebral artery occlusion in the rat. *J Cereb Blood Flow Metab* 6: 676-683, 1986.*
92. **Hakim AM** and Arrieta M: Cerebral acidosis in focal ischemia: I - A method for the simultaneous measurement of local cerebral pH with cerebral glucose utilization or cerebral blood flow in the rat. *J Cereb Blood Flow Metab* 6: 667-675, 1986.*
93. Evans AC, Diksic M, Yamamoto YL, Kato A, Dagher A, Redies C and **Hakim AM**: Effect of vascular activity in the determination of rate constants for the uptake of ^{18}F -labeled 2-fluoro-2-deoxy-D-glucose: Error analysis and normal values in older subjects. *J Cereb Blood Flow Metab* 6: 724-738, 1986. ***

94. **Hakim AM**: Effect of thiamine deficiency and its reversal on cerebral blood flow in the rat. Observations on the phenomena of hyperperfusion, 'no-reflow' and delayed hypoperfusion. J Cereb Blood Flow Metab 6: 79-85, 1986.*
95. **Hakim AM**, Arrieta MJ, Cooper BA and Pappius HM: Effect of folate deficiency on local cerebral glucose utilization in the rat. J Neurochem 42: 1582-1587, 1984.
96. Kobatake K, Sako K, Izawa M, Yamamoto Y and **Hakim AM**: Autoradiographic determination of brain pH following middle cerebral artery occlusion in the rat. Stroke 15: 540-547, 1984.**
97. **Hakim AM**: The induction and reversibility of cerebral acidosis in thiamine deficiency. Ann Neurol 16: 673-679, 1984.*
98. Hart RG, Lockwood KI, **Hakim AM**, et al.: Immediate anticoagulation of embolic stroke: Brain hemorrhage and management options. Cerebral Embolism Study Group. Stroke 15: 779-789, 1984.*
99. Kobatake K, Sako K, Izawa M, Yamamoto Y and **Hakim AM**: Autoradiographic determination of brain pH following middle cerebral artery occlusion in the rat. Stroke 15: 540-547, 1984.**
100. **Hakim AM**, Ryder-Cooke A and Melanson D: Sequential computerized tomographic appearance of strokes. Stroke 14: 893-897, 1983.*
101. **Hakim AM**, Furlan AJ, Hart RG, et al.: Immediate anticoagulation of embolic stroke: A randomized trial. Cerebral Embolism Study Group. Stroke 14: 668-676, 1983.*
102. **Hakim AM**, Carpenter S and Pappius HM: Metabolic and histological reversibility of thiamine deficiency. J Cereb Blood Flow Metab 3: 468-477, 1983.*
103. **Hakim AM** and Pappius HM: Sequence of metabolic, clinical and histological events in experimental thiamine deficiency. Ann Neurol 13: 365-375, 1983.*
104. **Hakim AM**, Cooper BA, Rosenblatt DS and Pappius HM: Local cerebral glucose utilization in two models of B12 deficiency. J Neurochem 40: 1155-1160, 1983.*
105. Hill R, Martin J and **Hakim AM**: Acute respiratory failure in motor neuron disease. Arch Neurol 40: 30-32, 1983.**
106. **Hakim AM** and Pappius HM: The effect of thiamine deficiency on local cerebral glucose utilization. Ann Neuro 9: 334-339, 1981.*
107. **Hakim AM**, Moss G and Scuderi D: The pentose phosphate pathway in brain during development. Biol Neonate 37: 15-21, 1980.*
108. **Hakim AM** and Mathieson G: Dementia in Parkinson disease. A neuropathologic study. Neurology 29: 1209-1214, 1979.*
109. **Hakim AM** and Mathieson G: Basis of dementia in Parkinson's disease. Lancet 2(8092 Pt. 1): 729, 1978.*
110. **Hakim AM** and Moss G: Cerebral effects of barbiturate - shift from "energy" to synthesis metabolism for cellular viability. Surg Forum 27: 497-499, 1976.*
111. **Hakim AM**, Moss G and Gollomp SM: The effect of hypoxia on the pentose phosphate pathway in brain. J Neurochem 26: 683-688, 1976.*
112. **Hakim AM** and Moss G: The effect of ether anesthesia on cerebral glucose metabolism - The pentose phosphate pathway. Anesthesiology 40: 261-267, 1974.*
113. **Hakim AM** and Moss G: Direct *in vivo* quantitation of the pentose phosphate pathway in brain. Trans NY Acad Sci 34: 473-484, 1972.*

Invited and Non-Refereed Articles:

1. **Hakim AM**, Sharma M, Thompson C. Chapter – Gene and Cell Therapy in Stroke. Book: Acute Stroke Treatment [2nd ed] ed. By Bogousslavsky, 2001. *
2. **Hakim AM**. Prognosis 2020: what lies ahead in four key areas of rehab medicine – Stroke. Rehab & Community Care management, 38-39, 2001. *
3. Morley P, Tauskela JS and **Hakim AM**: Calcium overload. In: Cerebral Ischemia: Molecular and Cellular Pathophysiology, W Walz (Ed) Humana Press, Totowa, NJ pp. 69-104, 1999. **
4. **Hakim AM**: Thrombolytics for stroke. Can Med Assoc J 159: 757-758, 1998.* (Letter to the Editor)

5. **Hakim AM**, Silver F, Hodgson C: Organized stroke care: A new era in stroke prevention and treatment. In: Stroke: costs, practices and the need for change. *Can Med Assoc J* 159 (Suppl. 6): 51, 1998. (Editorial for CMAJ Stroke Supplement)
6. **Hakim AM**: tPA: A cause for tentative celebration. *Can J Neuro Sci* 25: 179-180, 1998.* (Editorial)
7. **Hakim AM**: Ischemic penumbra: the therapeutic window. *Neurology* 8 (Suppl 3): S44-S46, 1998.* (Invited Article)
8. Akiyama K, **Hakim AM**: Gene therapy in stroke. In: *Acute Stroke Treatment*, J Bogousslavsky (Ed), Martin Dunitz Ltd., London. pp. 163-170, 1997.*
9. Matsushima K, Schmidt-Kastner R, **Hakim AM**: Genes and Cerebral Ischemia: Therapeutic Perspectives. *Cerebrovasc Dis* 6: 119-127, 1996.*
10. Morley P, Hogan MJ, **Hakim AM**: Calcium-mediated mechanisms of ischemic injury and protection. *Brain Pathol* 4: 37-47, 1994.**
11. Sharma M, **Hakim AM**: The Neuroscience of Cerebral Ischemia. In: *Current Review of Cerebrovascular Disease*, M Fisher and J Bogousslavsky (Eds), Current Medicine Inc., Philadelphia. pp. 15-22, 1993.*
12. Hogan MJ, Gjedde A, **Hakim AM**: Activity of the dihydropyridine calcium channels following cerebral ischemia. In: *Arzneimittel-Forschung / Drug Research*. 41(3a): 332-333, 1991.*
13. Hogan M, **Hakim AM**: Pathophysiology of stroke: laboratory and clinical insights. In: *Current Opinion in Neurology and Neurosurgery* 3: 46-49, 1990.* (Invited Article)
14. Etienne P, **Hakim AM**: Clinical Testing of Compounds Modifying Acute and Chronic Neurodegeneration in the CNS. *Prog Clin Biolog Res* 361: 387-407.**
15. **Hakim AM**, Silver F, Hodgson C. Commentary. Is Canada falling behind international standards for stroke care? *CMAJ Sep*. 1998; 159: 671-673.
16. **Hakim AM**: Letter. Thrombolytics for stroke. *CMAJ Oct*. 1998; 159: 757-a – 758.
17. **Hakim AM**: Hemodynamic and Metabolic Studies in Stroke. In: *Seminars in Neurology*, Volume 9(4): 286-292, 1989.*
18. Gjedde A, Kuwabara H, Berger L, Beil C, Evans AC, **Hakim AM**: Density of functioning cerebral capillaries in stroke patients, determined by PET. In: *Cerebral Ischemia and Calcium*. A Hartmann and W Kuschinsky (Eds). Springer-Verlag, Berlin, Heidelberg, pp. 337-349, 1989. **
19. **Hakim AM**. Gene Induction and protein synthesis in stroke. Invited contribution to *Handbook of Neurology*. Submitted - 2006. *
20. **Hakim AM**, Berger L, Popow D, Gjedde A: Nimodipine binding in cerebral ischemia. In: *Cerebral Ischemia and Calcium*. A Hartmann and W Kuschinsky (Eds). Springer-Verlag, Berlin, Heidelberg, pp. 206-209, 1989.*
21. **Hakim AM**, Shoubridge EA: Cerebral acidosis in focal ischemia. *Cerebrovasc Brain Metab Rev* 1: 115-132, 1989* (Invited Article)
22. Meyer E, Thompson CJ, Marrett S, **Hakim AM**: Field of view for gamma ray detectors and extended radiation sources. *J Cereb Blood Flow Metab* 8: 144-145, 1988.** (Letter to the Editor)
23. Gjedde A, Beil C, Meyer E, Evans AC, **Hakim AM**: Density of capillaries in regions of the living human brain affected by stroke. In: *Cerebral Hyperemia and Ischemia*. M Tomita, T Sawada, H Naritomi and WD Heiss (Eds). *Excerpta Medica*, Amsterdam, pp. 91-102, 1988.**
24. Andreasen NC, Carson R, Diksic M, Evans A, Farde L, Gjedde A, **Hakim AM**, Lal S, Nair N, Sedvall G, Tune L and Wong D: Schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. *Schizophr Bull* 14: 471-484, 1988.**
25. **Hakim AM**, Baxter DW: Contemporary approaches to cerebrovascular disease. In: *Contributions to contemporary neurology: a tribute to Joseph Michael Foley*. RB Daroff and JP Conomy (Eds). Butterworth Publishers, Boston, pp. 87-90, 1988.*
26. **Hakim AM**: The cerebral ischemic penumbra. *Can J Neurol Sci*, Editorial Review 14: 557-559, 1987.* (Invited Article)
27. Abou-Madi MN, **Hakim AM**, Pokrupa RP, Meyer E, Diksic M, Yamamoto YL, Trop D: Evolution de l'ischmie cerebrale au cours des premieres quarante-huit heures. *Agressologie* 28: 205-208, 1987.**
28. Yamamoto YL, **Hakim AM**, Diksic M, Pokrupa R, Meyer E, Tyler JL, Evans AC, Worsley K, Thompson CJ, Feindel WH: Focal flow distribution in acute strokes: effects on regional

- metabolism and tissue pH. In: Functional Mapping of the Brain in Vascular Disorders. WD Heiss (Ed). Springer-Verlag, Berlin, pp. 85-105, 1985.**
29. Wolfe LS, Pappius HM, Pokrupa R, **Hakim AM**: Involvement of arachidonic acid metabolites in experimental brain injury. Identification of lipoxygenase products in brain. Clinical studies on prostacyclin infusion in acute cerebral ischemia. In: Advances in Prostaglandins, Thromboxane, and Leukotriene Research, Volume 15. O Hayaishi and S Yamamoto (Eds), Raven Press, New York, pp. 585-588, 1985. **